Skip to main content

Security report for fujifilmkyowakirin-biologics.com

FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. · Healthcare · Japan

Medium risk. 3 critical or high findings in Security headers, GDPR outside view and 1 other check.

Security score

73/100

Risk levelMedium

0–100, higher is better. How it is calculated

FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. is a medium-sized healthcare company specializing in biosimilar pharmaceuticals. The website serves as a corporate portal providing information about biosimilars, product pipelines, corporate data, and solutions. The company is positioned as a reputable player in the biosimilar market with established partnerships and product approvals in Japan and Europe. The website targets healthcare professionals, industry stakeholders, and potential partners. Technically, the website uses a traditional tech stack including jQuery, Slick Carousel, and marketing/analytics tools such as Marketo and Google Analytics. While the site is moderately optimized for performance and accessibility, some technical debt is evident, such as the use of an outdated jQuery version and lack of DNSSEC. The site is hosted securely with HTTPS but lacks advanced security headers. From a security perspective, the website demonstrates a basic but solid posture with HTTPS enforcement and domain transfer protections. However, it lacks explicit security policies, incident response contacts, and vulnerability disclosure mechanisms. The absence of cookie consent mechanisms despite having a cookie policy indicates partial privacy compliance. No direct contact emails or phone numbers are provided, with contact limited to an external form. Overall, the website is professional, trustworthy, and safe for general audiences. The AI score reflects good content quality and business credibility but highlights areas for security and privacy improvements. Strategic recommendations include upgrading outdated libraries, enabling DNSSEC, implementing security headers, and enhancing privacy compliance mechanisms.

Scanned

NIS2 and GDPR posture

GDPR outside view
68/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

3 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching fujifilmkyowakirin-biologics.com

This scan found 21 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
67
Security headers
45
Email security
85
DNS health
75
Network security
100
GDPR outside view
68
Average
73

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

FUJIFILM KYOWA KIRIN BIOLOGICS operates in the healthcare sector focusing on biosimilar pharmaceuticals, a growing market segment driven by patent expirations of biologic drugs. The company leverages strong brand partnerships with FUJIFILM and Kyowa Kirin, enhancing its market credibility. Its business model centers on biosimilar development, regulatory approvals, and commercialization. The website content and press releases indicate active product launches and regulatory milestones, suggesting growth and market penetration. The target customers include healthcare providers, pharmaceutical companies, and regulatory bodies. The company maintains a professional online presence with clear corporate branding and informational resources, supporting its competitive positioning in the biosimilar industry.

Security posture

The website's security posture is moderate. HTTPS is properly implemented, and domain transfer protections are in place. However, the lack of DNSSEC and security headers reduces overall security robustness. The use of an outdated jQuery version introduces potential vulnerabilities. No explicit security or incident response policies are published, and no vulnerability disclosure or security.txt files are present. Privacy compliance is partial, with cookie policies but no consent mechanisms. The absence of direct contact information for security incidents limits incident response readiness. Overall, the site is secure enough for general corporate use but would benefit from enhanced security controls and transparency.

Recommendations

  1. Enable DNSSEC on the domain to improve DNS security and prevent spoofing.
  2. Upgrade jQuery and other JavaScript libraries to current secure versions to mitigate known vulnerabilities.
  3. Implement security headers such as Content-Security-Policy, X-Content-Type-Options, and Strict-Transport-Security to harden the website.
  4. Add a cookie consent mechanism to comply with GDPR and other privacy regulations.
  5. Publish explicit security policies and incident response contact information to improve transparency and readiness.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
Description
The website of FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. providing information about biosimilars, products, corporate data, and solutions related to biosimilar pharmaceuticals.
Key services
Biosimilar development, Product pipeline management, Corporate solutions related to biosimilars
Content quality
good
Branding
consistent

Technology

Stack
jQuery 1.9.0, Slick Carousel, Marketo Munchkin tracking, Google Analytics, Google Tag Manager
Performance
moderate
Mobile
basic
Accessibility
basic
SEO
good

Security

Observed score
70/100
Good practices seen
  • HTTPS enforced
  • Domain status clientTransferProhibited to prevent unauthorized transfers

Analytics and tracking

Services
Google Analytics, Marketo Munchkin
Tracking level
moderate
Privacy practices
basic

Advertising

Tracking pixels
Marketo Munchkin
Marketing tools
Marketo
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Content is professionally presented and relevant to biosimilar pharmaceuticals.
  3. No direct email or phone contact information found on the main site; contact is via external form.
  4. No explicit security or incident response policies published.
  5. Use of standard marketing and analytics tools with moderate user tracking.
  6. No security.txt or vulnerability disclosure policy found.
  7. No social media links detected in the provided content.
  8. Domain and website branding are consistent and trustworthy.
Technical notes

Notes

The website uses a classic web technology stack with jQuery 1.9.0, Slick Carousel for UI elements, and integrates marketing and analytics tools like Marketo Munchkin and Google Analytics. The site is served over HTTPS with no visible CMS detected, suggesting a custom or static site architecture. Performance is moderate with asynchronous script loading but could be improved with modern frameworks and optimization. Accessibility features are basic, including font resizing and skip links. SEO is adequately addressed with meta tags and structured navigation. Technical debt is present due to outdated libraries and missing DNSSEC. Hosting details are not explicit but likely managed internally or through Fujifilm's infrastructure.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with fujifilmkyowakirin-biologics.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review fujifilmkyowakirin-biologics.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.